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*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, U.K.
†Department of Neurosurgery, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, U.S.A.
‡Manton Center for Orphan Disease Research, Children’s Hospital Boston, Boston, MA 02115, U.S.A.
Precise homoeostasis of the intracellular concentration of Cl−
is achieved via the co-ordinated activities of the Cl− influx and
efflux. We demonstrate that the WNK (WNK lysine-deficient
protein kinase)-activated SPAK (SPS1-related proline/alanine-
rich kinase)/OSR1 (oxidative stress-responsive kinase 1) known to
directly phosphorylate and stimulate the N[K]CCs (Na+ –K+ ion
co-transporters), also promote inhibition of the KCCs (K+ –Cl−
co-transporters) by directly phosphorylating a recently described
C-terminal threonine residue conserved in all KCC isoforms [Site-
2 (Thr1048)]. First, we demonstrate that SPAK and OSR1, in the
presence of the MO25 regulatory subunit, robustly phosphorylates
all KCC isoforms at Site-2 in vitro. Secondly, STOCK1S-50699, a
WNK pathway inhibitor, suppresses SPAK/OSR1 activation and
KCC3A Site-2 phosphorylation with similar efficiency. Thirdly, in
ES (embryonic stem) cells lacking SPAK/OSR1 activity, endogen-
ous phosphorylation of KCC isoforms at Site-2 is abolished and
these cells display elevated basal activity of 86Rb+ uptake that was
not markedly stimulated further by hypotonic high K+ conditions,
consistent with KCC3A activation. Fourthly, a tight correlation ex-
ists between SPAK/OSR1 activity and the magnitude of KCC3A
Site-2 phosphorylation. Lastly, a Site-2 alanine KCC3A mutant
preventing SPAK/OSR1 phosphorylation exhibits increased
activity. We also observe that KCCs are directly phosphorylated
by SPAK/OSR1, at a novel Site-3 (Thr5 in KCC1/KCC3 and
Thr6 in KCC2/KCC4), and a previously recognized KCC3-
specific residue, Site-4 (Ser96). These data demonstrate that the
WNK-regulated SPAK/OSR1 kinases directly phosphorylate the
N[K]CCs and KCCs, promoting their stimulation and inhibition
respectively. Given these reciprocal actions with anticipated net
effects of increasing Cl− influx, we propose that the targeting
of WNK–SPAK/OSR1 with kinase inhibitors might be a novel
potent strategy to enhance cellular Cl− extrusion, with potential
implications for the therapeutic modulation of epithelial and
neuronal ion transport in human disease states.
Key words: γ -aminobutyric acid (GABA), blood pres-
sure/hypertension, ion homoeostasis, K+ –Cl− co-transporter 2
(KCC2), K+ –Cl− co-transporter 3 (KCC3), Na+ –Cl− co-trans-
porter (NCC), Na+ –K+ –2Cl− co-transporter 1 (NKCC1), protein
kinase, signal transduction.
INTRODUCTION
In eukaryotic cells, the regulation of intracellular Cl−
concentration ([Cl− ]i) is important for multiple essential cellular
processes, including cell volume homoeostasis, which counters
excessive shrinkage or swelling amidst changes in extracellular
tonicity and/or intracellular ion content [1]. The SLC12A (solute
carrier family 12) family of electroneutral CCCs (cation–Cl− co-
transporters), by transporting Cl− against or with its electrochem-
ical gradient, are critical determinants of [Cl− ]i [2]. Cl− influx is
powered by the Na+ -driven CCC members, which includes the
NCC (Na+ –Cl− co-transporter) in the distal convoluted tubule of
the kidney [3,4], the NKCC2 (Na+ –K+ –2Cl− co-transporter 2)
in the thick ascending limb of the kidney [5] and the ubiquitously
expressed NKCC1 [6–8]. Cl− efflux is powered by the K+ -driven
CCCs, which include four different K+ –Cl− co-transporters
(KCC1–KCC4) [9], including the neuron-specific KCC2. There
are two well-studied splice variants of KCC2, termed KCC2 and
KCC2A [10], and of KCC3, termed KCC3 and KCC3A [11]. The
physiological importance of the CCCs is illustrated by the human
Mendelian diseases or mouse phenotypes that result from their
mutation or dysfunction [12], and that two CCCs are the targets
of the most commonly used drugs in medicine, the loop-diuretic
furosemide (inhibiting NKCC2) and thiazide diuretics (inhibiting
NCC) [13]. The activities of the NCC/NKCC1/NKCC2 (i.e.
N[K]CCs [Na+ –K+ ion co-transporters]) and KCCs are
reciprocally regulated by protein (de)phosphorylation [9,14,15].
Phosphorylation activates NCC/NKCC1/NKCC2, but inhibits
KCCs [9,15–17]. Dephosphorylation has the opposite effect. This
reciprocal regulation of Na+ - and K+ -driven CCCs ensures that
cellular Cl− influx and efflux is tightly co-ordinated [9,18]. The
importance of this mechanism is exemplified by its evolutionary
conservation from worms to humans [19].
Experiments have defined the WNK (WNK lysine-deficient
protein kinase) serine/threonine kinases [20] and their down-
stream kinase substrates SPAK [SPS1-related proline/alanine
rich kinase; also known as STK39 (serine/threonine kinase 39)]/
OSR1 (oxidative stress-responsive kinase 1) [21] as the essential
phospho-regulators that stimulate N[K]CC activity. WNK
isoforms activate the two highly related SPAK and OSR1
Abbreviations: CCC, cation–Cl− co-transporter; CCT, conserved C-terminal; CTD, C-terminal cytoplasmic domain; ERK1, extracellular-signal-regulated
kinase 1; ES, embryonic stem; HEK, human embryonic kidney; HRP, horseradish peroxidase; KCC, K+ –Cl− co-transporter; LDS, lithium dodecyl sulfate;
NCC, Na+ –Cl− co-transporter; N[K]CC, Na+ –K+ ion co-transporter; NKCC, Na+ –K+ –2Cl− co-transporter; NTD, N-terminal cytoplasmic domain; OSR1,
oxidative stress-responsive kinase 1; SLC12, solute carrier family 12; SPAK, SPS1-related proline/alanine-rich kinase; TTBS, Tris-buffered saline containing
Tween 20; WNK, WNK lysine-deficient protein kinase; XIC, extracted ion chromatogram.
1 Correspondence may be addressed to either of these authors (email d.r.alessi@dundee.ac.uk or j.c.zhang@dundee.ac.uk).
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proteins [22] by phosphorylating a critical threonine residue
(SPAK Thr233 and OSR1 Thr185) within their catalytic T-loop
motif [23,24]. SPAK and OSR1 also interact with the scaffolding
protein MO25 [also known as CAB39 (Ca2 + -binding protein 39)]
that enhances their catalytic activity over 100-fold [25]. SPAK
and OSR1 bind NCC, NKCC1 and NKCC2 via a unique CCT
(conserved C-terminal) docking domain that recognizes highly
conserved RFXV/I motifs at the N-terminal domain of these
CCCs [4–6,26–28]. The CCT domain also plays a critical role in
enabling SPAK/OSR1 to be activated by interacting with RFXV/I
motifs on WNK isoforms [24,26,29]. Recently, an inhibitor
(STOCK1S-50699) that interacts with the CCT domain of SPAK
and OSR1 and consequently prevents their activation by WNK
kinases has been shown to potently suppress SPAK/OSR1 activity
and NCC/NKCC1 phosphorylation [30]. WNK isoforms, and
hence SPAK/OSR1, are activated rapidly following hypertonic
or hypotonic low Cl− conditions [3,24,31]. Following activation,
SPAK/OSR1 phosphorylate a cluster of conserved threonine
residues in the NTD (N-terminal cytoplasmic domain) of the
N[K]CCs [25].
In the kidney, the WNK–SPAK/OSR1-mediated activation of
NCC and NKCC2, which together mediate ∼25% of renal
salt reabsorption, is critical for extracellular volume (influencing
blood pressure) and electrolyte homoeostasis. The importance
of this pathway in human renal physiology is underscored by
the findings that: (i) gain-of-function mutations in WNK1 and
WNK4 resulting in increased NCC and NKCC2 activities cause
a Mendelian syndrome featuring thiazide-sensitive hypertension
and hyperkalaemia (pseudohypoaldosteronism type II, also
known as PHAII [32]); (ii) loss-of-function mutations in NCC [33]
and NKCC2 [34] cause Gitelman’s and Bartter’s type 1 syndromes
respectively, featuring hypotension and hypokalaemia; and (iii)
a mutation of NCC at a residue (T60M) that ablates the key
activating WNK-regulated SPAK/OSR1 phosphorylation event
causes Gitelman’s syndrome in Asian people [35]. Moreover,
SPAK-knockout mice [36], or knockin mice expressing a form
of SPAK or OSR1 that cannot be activated by WNK kinase
isoforms [37], exhibit low blood pressure and are resistant to
hypertension when crossed to animals bearing a PHAII-causing
knockin mutation that enhances WNK4 expression [38].
In contrast with the N[K]CCs, the direct mediators of KCC
phospho-regulation are not known, although early experiments
suggested the WNK–SPAK/OSR1 kinases may be involved [39–
41]. Work to date indicates that two threonine residues that
are conserved in all KCC isoforms, termed Site-1 (Thr991 in
KCC3) and Site-2 (Thr1048 in KCC3), both located within the
CTD (C-terminal cytoplasmic domain), play a critical role in
controlling the activity of the KCCs [42]. Hypotonic high K+
conditions that activate KCC isoforms induce a rapid and robust
dephosphorylation of Site-1 and Site-2 [42]. Consistent with
these sites representing critical regulatory residues, mutation of
Site-1 and Site-2 to alanine in KCC3 results in a constitutively
active co-transporter [42]. The identity of the protein kinases that
phosphorylate Site-1 and Site-2, however, are currently unknown,
although the WNK1 signalling pathway has been implicated,
as siRNA-mediated knockdown of WNK1 partially suppressed
the phosphorylation of these residues in KCC3 [42]. Consistent
with a role for WNK isoforms in controlling KCC activity,
overexpression of WNK3 and WNK4 in oocytes and mammalian
cells leads to the inhibition of KCC isoforms, and kinase-dead
overexpression of WNK3 was found to potently stimulate KCC
activity [39,40,43–45].
In the present study, we explore the mechanism by which
WNKs might regulate KCC phosphorylation. Our data reveal
for the first time that the WNK-controlled SPAK/OSR1 act as
direct phosphorylators and major regulators of the KCC isoforms,
and explain how activation of the WNK signalling pathway
can co-ordinately regulate Cl− influx and efflux by reciprocally
controlling the SLC12 family N[K]CC and KCC isoforms. Given
these reciprocal actions with anticipated net effects of increasing
Cl− influx, we propose that inhibition of the WNK–SPAK/OSR1
signalling pathway might be a potent strategy to enhance cellular
Cl− extrusion, with potential therapeutic implications.
MATERIALS AND METHODS
Antibodies
The following antibodies were raised in sheep and affinity-
purified on the appropriate antigen by the Division of Signal
Transduction Therapy Unit at the University of Dundee: anti-
KCC1 total antibody (residues 1–118 of human KCC1),
anti-KCC2A total antibody (residues 1–119 of human
KCC2A), anti-KCC3A total antibody (residues 1–175 of hu-
man KCC3A), anti-KCC4 total antibody (residues 1–117
of human KCC4), anti-KCC3A phospho-Ser96 antibody
[residues 89–103 of human KCC3A phosphorylated at
Ser96; IEDLSQN(S)ITGEHSQ], anti-KCC3A phospho-Thr991
[residues 984–998 of human KCC3A phosphorylated at
Thr991; SAYTYER(T)LMMEQRSRR], anti-KCC3A phospho-
Thr1048 (residues 1041–1055 of human KCC3A phosphorylated
at Thr1048; CYQEKVHM(T)WTKDKYM), anti-NKCC1 total
antibody (residues 1–288 of human NKCC1), anti-NKCC1
phospho-Thr203/Thr207/Thr212 antibody [residues 198–217 of
human NKCC1 phosphorylated at Thr203, Thr207 and
Thr212; HYYYD(T)HTN(T)YYLR(T)FGHNT], anti-WNK1 total
antibody (residues 2360–2382 of human WNK1), anti-WNK1
phospho-Ser382 antibody [residues 377–387 of human WNK1
phosphorylated at Ser382; ASFAK(S)VIGTP]; anti-SPAK total
antibody (full-length GST-tagged human SPAK protein), anti-
SPAK/OSR1 (S-motif) phospho-Ser373/Ser325 antibody [residues
367–379 of human SPAK; RRVPGS(S)GHLHKT; highly similar
to residues 319–331 of human OSR1 in which the sequence
is RRVPGS(S)GRLHKT] and anti-ERK1 (extracellular-signal-
regulated kinase 1) total antibody (full-length human ERK1
protein). The anti-FLAG antibody (catalogue number F1804) was
purchased from Sigma–Aldrich. Secondary antibodies coupled
to HRP (horseradish peroxidase) used for immunoblotting were
obtained from Pierce. IgG used in control immunoprecipitation
experiments was affinity-purified from pre-immune serum using
Protein G–Sepharose.
Buffers
Buffer A contained 50 mM Tris/HCl (pH 7.5) and 0.1 mM EGTA.
Lysis buffer was 50 mM Tris/HCl (pH 7.5), 1 mM EGTA, 1 mM
EDTA, 50 mM sodium fluoride, 5 mM sodium pyrophosphate,
1 mM sodium orthovanadate, 1% (w/v) Nonidet P40, 0.27 M
sucrose, 0.1% 2-mercaptoethanol and protease inhibitors (1 tablet
per 50 ml). TTBS (Tris-buffered saline containing Tween 20)
was Tris/HCl (pH 7.5), 0.15 M NaCl and 0.2% Tween 20. SDS
sample buffer was 1× NuPAGE LDS sample buffer (Invitrogen),
containing 1% (v/v) 2-mercaptoethanol. Isotonic high potassium
buffer was 95 mM NaCl, 50 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
1 mM Na2HPO4, 1 mM Na2SO4 and 20 mM Hepes (pH 7.4).
Hypotonic high potassium buffer was 80 mM KCl, 1 mM CaCl2,
1 mM MgCl2, 1 mM Na2HPO4, 1 mM Na2SO4 and 20 mM Hepes
(pH 7.4). Isotonic buffer was 135 mM NaCl, 5 mM KCl, 0.5 mM
CaCl2, 0.5 mM MgCl2, 0.5 mM Na2HPO4, 0.5mM Na2SO4
and 15 mM Hepes (pH 7.5). Hypotonic low chloride buffer
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was 67.5 mM sodium gluconate, 2.5 mM potassium gluconate,
0.25 mM CaCl2, 0.25 mM MgCl2, 0.5 mM Na2HPO4, 0.5 mM
Na2SO4 and 7.5 mM Hepes (pH 7.5).
Plasmids
Full-length human KCCs isoforms were amplified employing
SuperScript III (Invitrogen) from placenta total RNA (Stratagene)
using the appropriate oligonucleotides. The RT–PCR (reverse
transcription–PCR) products were ligated into the pCR2.1-
TOPO vector and sequenced. The sequence-verified KCCs were
subcloned into bacterial (pGEX-6P-1) and mammalian (pCMV5)
expression vectors using BamHI and NotI. Required amino acid
mutations were introduced into the pCR2.1-TOPO clone using
site-directed mutagenesis by QuikChange method (Stratagene),
but substituting the Taq enzyme with KOD Hot Start DNA
polymerase (Novagen). Oligonucleotides were obtained from
Invitrogen Life Sciences. DNA sequencing was performed by
The Sequencing Service, College of Life Sciences, University of
Dundee (http://www.dnaseq.co.uk).
Cell culture, transfections and stimulations
HEK (human embryonic kidney)-293 cells were cultured
on 10-cm-diameter dishes in DMEM (Dulbecco’s modified
Eagle’s medium) supplemented with 10% (v/v) FBS, 2 mM L-
glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin.
For transfection experiments, each dish of adherent HEK-293
cells was transfected with 20 μl of 1 mg/ml polyethylenimine
(Polysciences) and 5–10 μg of plasmid DNA as described
previously [46]. At 36 h post-transfection cells were stimulated
with either control isotonic or hypotonic medium for a period of
30 min. Cells were lysed in 0.3 ml of ice-cold lysis buffer/dish,
lysates were clarified by centrifugation at 4 ◦C for 15 min
at 26000 g and the supernatants were frozen in aliquots in
liquid nitrogen and stored at − 20 ◦C. Protein concentrations
were determined using the Bradford method. Where indicated
cells were treated with the indicated concentrations of the
SPAK/OSR1 CCT domain inhibitor STOCK1S-50699 [30],
which was purchased from InterBioScreen.
Expression and purification of OSR1 T185E and D164A, SPAK
D212A, and KCCs N-terminal and C-terminal domains in
Escherichia coli cells
All pGEX-6P-1 constructs were transformed into BL21 E. coli
cells and 1-litre cultures were grown at 37 ◦C in LB broth
containing 100 μg/ml ampicillin until the attenuance at 600 nm
was 0.8. IPTG (30 μM) was then added and the cells were cultured
for a further 16 h at 26 ◦C. Cells were isolated by centrifugation
(4 ◦C for 30 min at 3500 g), resuspended in 40 ml of ice-cold
lysis buffer and lysed in one round of freeze–thawing, followed by
sonication (Branson Digital Sonifier; ten 15-s pulses with a setting
of 45% amplitude) to fragment DNA. Lysates were centrifuged
at 4 ◦C for 15 min at 26000 g. The GST-fusion proteins were
affinity-purified on 0.5 ml of glutathione–Sepharose and eluted in
buffer A containing 0.27 M sucrose and 20 mM glutathione.
Immunoblotting and phospho-antibody immunoprecipitation
Cell lysates (15 μg) in SDS sample buffer were subjected
to electrophoresis on polyacrylamide gels and transferred on to
nitrocellulose membranes. The membranes were incubated for
30 min with TTBS containing 5% (w/v) non-fat powdered
skimmed milk. The membranes were then immunoblotted in 5%
(w/v) non-fat powdered skimmed milk in TTBS with the indicated
primary antibodies overnight at 4 ◦C. Sheep antibodies were used
at a concentration of 1–2 μg/ml. The incubation with phospho-
specific sheep antibodies was performed with the addition of
10 μg/ml of the dephospho-peptide antigen used to raise the
antibody. The blots were then washed six times with TTBS
and incubated for 1 hour at room temperature (15–20 ◦C) with
secondary HRP-conjugated antibodies diluted 5000-fold in 5%
(w/v) non-fat powdered skimmed milk in TTBS. After repeating
the washing steps, the signal was detected using an ECL reagent.
Immunoblots were developed using a film automatic processor
(SRX-101; Konica Minolta Medical) and films were scanned with
a 600 d.p.i. resolution on a scanner (PowerLook 1000; UMAX).
Figures were generated using Photoshop/Illustrator (Adobe).
For phospho-antibody immunoprecipitation, KCC isoforms were
immunoprecipitated from indicated cell extracts. An aliquot
(2 mg) of the indicated clarified cell extract was incubated
with 15 μg of the indicated phospho-specific KCC antibody
conjugated to 15 μl of Protein G–Sepharose in the presence of
20 μg of the dephosphorylated peptide encompassing the residues
on KCC that the antibody was raised against. Incubation was for
2 h at 4 ◦C with gentle agitation, and the immunoprecipitates were
washed three times with 1 ml of lysis buffer containing 0.15 M
NaCl and twice with 1 ml of buffer A. Bound proteins were eluted
with 1× LDS sample buffer.
Mapping phosphorylation sites of KCCs by active SPAK
KCC1 (residues 1–118), KCC1 (residues 872–1085), KCC2A
(residues 1–119), KCC2A (residues 852–1039), KCC3A
(residues 1–117), KCC3A (residues 886–1141), KCC4 (residues
1–174) and KCC4 (residues 872–1083) (10 μg of each) purified
from E. coli cells were incubated with active SPAK [Carna
Biosciences STLK3 (STK39); product number 07-130] (0.5 μg)
or kinase-inactive SPAK–SPAK [D212A] (0.5 μg) also purified
from E. coli cells, at 30 ◦C for 60 min in buffer A containing
10 mM MgCl2, 0.1 mM [γ 32P]ATP (approximately 15000
c.p.m./pmol) in a total reaction volume of 25 μl. The reaction
was terminated by the addition of LDS sample buffer. DTT was
added to a final concentration of 10 mM, the samples heated
at 95 ◦C for 5 min and cooled for 20 min at room temperature.
Iodoacetamide was then added to a final concentration of 50 mM
and the samples left in the dark for 30 min at room temperature
to alkylate the cysteine residues. The samples were subjected to
electrophoresis on a Bis-Tris 10% polyacrylamide gel, which
was stained with Colloidal Blue and then autoradiographed.
The corresponding phosphorylated bands were excised, cut into
smaller pieces and washed sequentially for 10 min on a vibrating
platform with 1 ml of each of the following: water, 1:1 (v/v)
mixture of water and acetonitrile, 0.1 M ammonium bicarbonate,
1:1 mixture of 0.1 M ammonium bicarbonate and acetonitrile, and
finally acetonitrile. The gel pieces were dried before incubation for
16 h at 30 ◦C in 25 mM triethylammonium bicarbonate containing
5 μg/ml trypsin as described previously [47]. Following tryptic
digestion, >95% of the 32P radioactivity incorporated in the gel
bands was recovered and the samples were chromatographed on a
Vydac 218TP5215 C18 column (Separations Group) equilibrated
in 0.1% trifluoroacetic acid in water. The column was developed
with a linear acetonitrile gradient at a flow rate of 0.2 ml/min and
fractions of 0.1 ml were collected. Some phosphopeptide fractions
(Tables 1 and 2) were purified further by immobilized metal-
chelate affinity chromatography on Phos-Select resin (Sigma) as
described previously [48].
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Table 1 SPAK in the presence of MO25 phosphorylates KCC isoforms at two conserved Site-2 and Site-3 residues
The NTD and CTD of the indicated KCC isoforms were phosphorylated by SPAK (except for 32P cycle release data indicated with an asterisk that was phosphorylated by OSR1) in the presence of
MO25 with either radioactive [γ 32P]ATP or non-radioactive Mg-ATP. Phosphorylated fragments were trypsin digested and the resulting tryptic peptides were isolated by HPLC for the 32P-labelled
ones. The identity and site of phosphorylation was determined by a combination of MS and solid-phase Edman sequencing. Non-radioactive KCC fragments phosphorylated by SPAK were analysed
by orbitrap MS. The deduced amino acid sequence of each peptide is shown and the phosphorylated residue is underlined and in bold font. The resultant data was searched using the Mascot search
algorithm (http://www.matrixscience.com) run on a local server. For conservation and location of sites see Figure 2. It should be noted that although experiments were done with the shorter KCC3A
splice variant that lacks nine N-terminal residues, in order to be consistent with most previous literature studies, numbering of residues is based on the nine-residue-longer KCC3 variant.
32P HPLC Edmman sequencing MS (orbitrap)
Sample Phosphopeptide Mascot score Cycle of 32P release Mascot score m/z (observed) Phosphorylation site
NTD (KCC1) SDLEVLFQGPLGSTSMPHFTVVPVDGPR 90* 20* 82 1531.75 Thr5 (Site-3)
CTD (KCC1) IQMTWTR 27 4 26 508.22 Thr983 (Site-2)
NTD (KCC2A) RFTVTSLPPAGPAR 61 3 66 775.39 Thr6 (Site-3)
CTD (KCC2A) VHLTWTK Not detected Not detected 20 482.73 Thr1030 (Site-2)
NTD (KCC3A) TSHPQDVIEDLSQNSITGEHSQLLDDGHK 53 15 55 1094.16 Ser96 (Site-4)
CTD (KCC3A) VHMTWTK Not detected Not detected 6 491.71 Thr1048 (Site-2)
CTD (KCC4) VQMTWTR Not detected Not detected 40 501.21 Thr980 (Site-2)
Table 2 Summary of other in vitro SPAK phosphorylation sites that were identified, but not investigated further in the present study
Analysis was undertaken as described in the legend of Table 1. For conservation and location of these sites see Figure 2. Peptides with a m/z (observed) marked with 1P correspond to peptide mass
with one phosphate and those with 2P correspond to a peptide with two phosphates. Phosphorylated residues are underlined and in bold font. Lower case m indicates oxidized methionine.
32P HPLC Edmman sequencing MS (orbitrap)
Sample Phosphopeptide Mascot score Cycle of 32P release Mascot score m/z (observed) Phosphorylation site(s)
CTD (KCC1) DKYMTETWDPSHAPDNFR Not performed Not performed 41 763.98 Thr991 or Thr993
NTD (KCC2A) NmALFEEEmDTSPmVSSLLSGLANYTNLPQGSR 43 12 or 26 Not performed 933.41 (1P) Ser83 or Thr92
NmALFEEEmDTSPmVSSLLSGLANYTNLPQGSR 65 11, 12,17 and 26 Not performed 1244.21 (1P) Thr77 and/or Ser78, and/or Ser83 and/or Thr92
NmALFEEEmDTSPmVSSLLSGLANYTNLPQGSR 42 11, 12,17 and 26 Not performed 1270.87 (2P) Thr77 and/or Ser78, and/or Ser83 and/or Thr92
NTD (KCC3A) mANYTNLTQGAKEHEEAENITEGK Not performed Not performed 57 925.40 Thr160
FMVTPTKIDDIPGLSDTSPDLSSR Not performed Not performed 25 891.42 Ser32
CTD (KCC4) TQAPPTPDKVQMTWTR Not performed Not performed 25 646.30 Thr 973
TQAPPTPDKVQMTWTR Not performed Not performed 24 968.95 Thr980 (Site-2) or Thr982
MS analysis
Isolated phosphopeptides were analysed by MS analysis as
follows. LC–MS/MS was performed using a linear ion trap-
orbitrap hybrid mass spectrometer (OrbiTrap Classic; Thermo
Fisher Scientific) equipped with a nanoelectrospray ion source
(Proxeon Biosystems or Thermo) and coupled to a Proxeon
EASY-nLC system. Peptides were typically injected on to a
Thermo/Dionex (part number 160321) Acclaim PepMap100
reverse-phase C18 3 μm column, 75 μm×15 cm, with a flow of
300 nl/min and eluted with a 40 min linear gradient of 95%
solvent A (2% acetonitrile and 0.1% formic acid in H2O) to 50%
solvent B (90% acetonitrile and 0.08% formic acid in H2O). The
instrument was operated with the ‘lock mass’ option to improve
the mass accuracy of precursor ions and data were acquired in the
data-dependent mode, automatically switching between MS and
MS/MS acquisition. Full scan spectra (m/z 300–1800) were
acquired in the orbitrap with resolution R = 60000 at m/z 400
(after accumulation to a target value of 500000). The five
most intense ions, above a specified minimum signal threshold,
based upon a low resolution (R = 15000) preview of the survey
scan, were fragmented by collision induced dissociation and
recorded in the linear ion trap (target value of 20000). Multi-
stage-activation was used to provide an MS3 scan of parent
ions showing a neutral loss of 48.9885, 32.6570 and 24.4942,
allowing for 2+ , 3+ and 4+ ions respectively. The resulting
MS3 scan was automatically combined with the relevant MS/MS
scan before data analysis using the Mascot search algorithm
(http://www.matrixscience.com) run on a local server.
32P-labelled phosphopeptide sequence analysis
The site of phosphorylation of the 32P-labelled peptides was
determined by solid-phase Edman degradation, on an Applied
Biosystems 494C sequencer, of the peptide coupled to Sequelon-
AA membrane (Applied Biosystems) as described previously
[49].
KCC3A phosphorylation sites in vivo identification
Fifteen 10-cm diameter dishes of HEK-293 cells were transfected
with 5–10 μg of the pCMV5 construct encoding human FLAG–
KCC3A using the polyethylenimine method [46]. The cells were
cultured for a further 36 h, treated with either basic or hypotonic
medium, and lysed in 0.3 ml of ice-cold lysis buffer. The pooled
lysate was clarified by centrifugation at 4 ◦C for 10 min at
26000 g. FLAG–KCC3A was affinity-purified by incubating
50 μl of FLAG–agarose beads with 10 mg of the clarified lysate
for 2 h at 4 ◦C. The immunoprecipitates were washed four times
with 1 ml of lysis buffer containing 0.15 M NaCl and twice with
1 ml of buffer A. Proteins were eluted from the FLAG beads
by the addition of 25 μl of 1× NuPAGE LDS (lithium dodecyl
sulfate) sample buffer to the beads. Eluted proteins were reduced
by the addition of 10 mM DTT and were prepared as described
above. For the identification of phosphorylation sites, the tryptic
digests were analysed by LC–MS on an Applied Biosystems 4000
QTRAP system with precursor ion scanning as described previ-
ously [50]. The resultant data were searched using the Mascot
search algorithm run on a local server. Tryptic phosphopeptides
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Figure 1 SPAK and OSR1, complexed to MO25α, directly phosphorylate KCC isoforms
The NTD and CTD of KCC1 (residues 1–118 and 872–1085 respectively), KCC2A (residues 1–119 and 852–1039 respectively), KCC3A (residues 1–175 and 886–1141 respectively), and KCC4
(residues 1–174 and 872–1083 respectively) were expressed in E. coli cells and incubated with an active SPAK purchased from Carna Biosciences which is co-expressed with WNK1 in Sf9 insect
cells and hence phosphorylated at Thr233 and therefore active (A) and OSR1 [T185E] (B), as well as the kinase-inactive (KI) forms of SPAK [D212A] (C) and OSR1 [D164A] (D) in the absence
or presence of a 10-molar excess of MO25α. Reactions were performed in the presence of Mg-[γ 32P]ATP for 60 min. Phosphorylation of substrates was analysed following electrophoresis of
the Coomassie Blue-stained bands (upper panels) and autoradiography (lower panels). Similar results were obtained in two separate experiments. Broken lines between autoradiographs and gels
indicate that the samples were run on separate gels. The bands corresponding to the NTD and CTD fragments are indicated by an asterisk. MW indicates the molecular mass (in kDa).
were also analysed as above under MS analysis and XICs
(extracted ion chromatograms) of the isolated phosphopeptides
were obtained from the MS RAW data files and analysed with
Thermo ScientificTM Xcalibur software Version 2.2. Observed
variations in charge states, oxidation states and partial cleavages
were taken into account when calculating the total XIC for a
particular phosphorylation site. The mass range used for the XICs
was the observed m/z value +− 10 p.p.m. of the relevant peptide.
86Rb+ -uptake assay in ES and HEK-293 cells
ES cells were plated in 12-well plates (2.4-cm diameter/well) and
the 86Rb+ -uptake assay was performed on cells that were 80%
confluent. HEK-293 cells were plated at a confluence of 50–60%
in 12-well plates (2.4-cm diameter per/well) and transfected with
wild-type or various mutant forms of full-length FLAG-tagged
human KCCs. Each well of HEK-293 cells was transfected with
2.5 μl of 1 mg/ml polyethylenimine and 1 μg of plasmid DNA.
The 86Rb+ -uptake assay was performed on the cells at 36 h
post-transfection. In both cases, culture medium was removed
from the wells and replaced with either isotonic or hypotonic
medium for 15 min at 37 ◦C. Cell medium was removed by
means of aspiration with a vacuum pump and replaced with
stimulating medium plus inhibitors including 1 mM ouabain and
0.1 mM bumetanide, to prevent 86Rb+ uptake via NKCC1, for
a further 15 min. After this period, the medium was removed
and replaced with isotonic medium plus inhibitors containing
2 μCi/ml 86Rb+ for 10 min at 37 ◦C. After this incubation
period, cells were rapidly washed three times with the respective
ice-cold non-radioactive medium. The cells were lysed in 300 μl
of ice-cold lysis buffer and 86Rb+ -uptake tracer activity was
quantified on a PerkinElmer liquid scintillation analyser.
RESULTS
SPAK and OSR1 complexed to MO25α phosphorylate multiple KCC
isoforms
KCC isoforms comprise a NTD and a CTD separated by a central
12 transmembrane region. We expressed the isolated NTD and
CTD of KCC1, KCC2A, KCC3A and KCC4 in E. coli cells
and tested whether these fragments could be phosphorylated by
SPAK in vitro. Phosphorylation reactions were undertaken in
the presence or absence of MO25α, the SPAK/OSR1 regulatory
subunit, which increases SPAK/OSR1 activity >100-fold [25].
Experiments revealed that SPAK phosphorylated the NTD and
CTD of all four KCC isoforms tested in the presence, but not in the
absence, of MO25α (Figure 1A). Consistent with phosphorylation
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Figure 2 Conserved and unique identified regulatory phospho-sites in KCC isoforms
Sequence alignment of KCC1, KCC2, KCC2A, KCC3, KCC3A and KCC4 isoforms that show the position of the in vitro and in vivo phosphorylation sites identified in the present study (boxed
residues). Boxed residues are phosphorylation sites that are listed in Tables 1–3. , in vitro phosphorylation sites listed in Tables 1 and 2. , in vivo KCC3A phosphorylation sites that are
dephosphorylated following exposure of cells to hypotonic high K+ conditions listed in Table 3., in vivo KCC3A phosphorylation sites that are not influenced by exposure of cells to hypotonic
high K+ conditions listed in Table 3., in vivo KCC3A phosphorylation sites that were identified by the Lifton group [42] to become dephosphorylated following exposure of cells to hypotonic
high K+ conditions., in vivo KCC3A phosphorylation sites that were previously identified [42] and not influenced by hypotonic high K+ conditions. It should be noted that as all experiments
were done with the shorter KCC3A splice variant that lacks nine amino acid N-terminal residues, in order to be consistent with most previous literature studies, numbering of residues for KCC3A is
based on the nine-residue-longer KCC3 variant.
of KCC fragments being mediated specifically by SPAK, the
kinase-dead SPAK [D212A] mutant failed to phosphorylate KCC
isoforms in the presence of MO25α (Figure 1B). OSR1, in the
presence, but not absence, of MO25α, also phosphorylated the
NTD and CTD of all KCC isoforms (Figure 1C). In contrast,
kinase-dead OSR1 [D164A] failed to phosphorylate all KCC
isoforms (Figure 1D). These data demonstrate that both SPAK
and OSR1 are capable of phosphorylating the NTD and CTD of
multiple KCC isoforms when complexed with MO25α.
Identification of in vitro SPAK/OSR1 phosphorylation sites
To map the sites that the SPAK–MO25α complex phosphorylates
on KCC isoforms, we performed phosphorylation reactions in
the presence of radioactive [γ 32P]ATP, and then digested them
with trypsin. The resulting 32P-labelled tryptic peptides were
isolated by HPLC and the identity and site of phosphorylation
was determined by employing a combination of MS and solid-
phase Edman sequencing (Figure 2, and Tables 1 and 2). We also
analysed directly the phosphorylation reactions using orbitrap MS
analysis to pinpoint residues phosphorylated by SPAK–MO25α
(Figure 2 and Table 1).
Notably, the SPAK–MO25α complex was found to
phosphorylate all KCC isoforms at the critical Site-2 (Thr983
in KCC1, Thr1030 in KCC2A, Thr1048 in KCC3A and Thr980 in
KCC4; Figure 2 and Table 1). SPAK–MO25α also phosphorylated
KCC1, KCC2A and KCC4 at a conserved N-terminal threonine
residue that we have termed Site-3 (Thr5 in KCC1 and Thr6
in KCC2A/KCC4; Figure 2). Site-3 is not conserved in the
KCC3A splice variant employed, but is conserved in the KCC3
splice variant (Thr5) (Figure 2). Consistent with previous findings
[51], SPAK–MO25α also phosphorylated KCC3A at Ser96 (Site-
4) within a motif not present in other KCCs (Figure 2). Our
analysis also revealed a limited number of other phosphorylation
sites observed in only single isoforms, which have not been
further investigated (Table 2). Importantly, we did not observe
phosphorylation of the critical Site-1 residues by SPAK–MO25α
in any of the KCC isoforms tested.
Mapping of KCC3A phosphorylation sites in vivo
We used MS orbitrap analysis of KCC3A transiently expressed
in HEK-293 cells that were stimulated with either hypotonic
low Cl− conditions (where phosphorylation of Site-1 and
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Table 3 In vivo KCC3A phosphorylation sites identified in the present study
N-terminal FLAG-tagged KCC3A was overexpressed in HEK-293 cells. At 36 h post-transfection, cells were treated with either hypotonic low Cl− or hypotonic high K+ conditions to induce
dephosphorylation and hence activation of the KCC3A isoform for 30 min. KCC3A was immunoprecipitated and after electrophoresis on a polyacrylamide gel and Colloidal Blue staining, the bands
corresponding to KCC3A were excised and digested with trypsin. Phosphorylated peptides were identified by combined MS and MS/MS analysis The data was searched using the Mascot search
algorithm run on a local server. The deduced amino acid sequence of each peptide is shown and the phosphorylated residue, where identified, is underlined and in bold font. The ratios of the
abundance of each phosphopeptide that was detected in hypotonic high K+ samples compared with the hypotonic low Cl− conditions was calculated using Xcalibur software. Lower case m indicates
oxidized methionine.The conservation and location of each phosphorylated residue is illustrated in Figure 2. It should be noted that although experiments were done with the shorter KCC3A splice
variant that lacks nine N-terminal residues, in order to be consistent with most previous literature studies, the numbering of residues is based on the nine-residue-longer KCC3 variant.
MS (orbitrap)
Phosphopeptide Mascot score (hypotonic high K+ ) m/z (observed) Phosphorylation site Xcalibur ratio (hypotonic low Cl− /hypotonic high K+ )
TLMMEQR 39 494.70 Thr991 (Site-1) >10-fold
VHMTWTK 31 491.71 Thr1048 (Site-2) >10-fold
NAYLNNSNYEEGDEYFDKNLALFEEEmDTRPK 75 1318.89 Ser129 No significant change
FMVTPTKIDDIPGLSDTSPDLSSR 87 891.42 Ser32 No significant change
IDDIPGLSDTSPDLSSR 74 934.42 Ser32 No significant change
FSSRESVPETSR 31 487.88 Ser50 No significant change
TSHPQDVIEDLSQNSITGEHSQLLDDGHKK 39 852.90 Ser96 (Site 4) No significant change
VSSLLNR 41 434.71 Ser148 No significant change
LTSIGSDEDEETETYQEK 92 1077.44 Ser1032 No significant change
AKSMEGFQDLLNMRPDQSNVR 47 839.38 Ser1064 No significant change
Site-2 should be maximal) or hypotonic high K+ conditions
(which should induce dephosphorylation of Site-1 and Site-2),
to map further KCC3A phosphorylation sites in vivo [42]. This
confirmed that hypotonic high K+ conditions did indeed induce
a >10-fold reduction in phosphorylation of Site-1 (Thr991) and
Site-2 (Thr1048) (Figure 2 and Table 3). Our analysis identified
a number of other phosphorylated residues on KCC3A whose
phosphorylation was not inhibited significantly by hypotonic
conditions (Figure 2 and Table 3). Several of these sites have
also been identified previously [42] (Figure 2).
Creation and characterization of phospho-specific KCC antibodies
To develop a tool that is able to monitor the phosphorylation
state of these critical KCC phospho-residues in cells and
tissues, we raised phospho-specific antibodies that recognize
the critical regulatory Site-1 (Thr991), Site-2 (Thr1048) or Site-
4 (Ser96) residues in KCC3A. The antibodies recognized by
immunoblot or immunoprecipitation (Figure 3A) wild-type
KCC3A overexpressed in HEK-293 cells, but not a mutant
version of KCC3A in which the phosphorylated residue was
changed to alanine. These antibodies confirm that treatment of
HEK-293 cells with hypotonic high K+ conditions for 30 min
induces almost complete dephosphorylation of KCC3A at Site-
1 (Thr991) and Site-2 (Thr1048) (Figure 3A). We observed that
hypotonic high K+ conditions induced a significantly more
moderate dephosphorylation of Site-4 (Ser96) compared with Site-
1 and Site-2 (Figure 3A). Individual mutation of Site-1 (Thr991),
Site-2 (Thr1048) or Site-4 (Ser96) did not significantly affect the
phosphorylation of the other sites (Figure 3A).
The residues surrounding Site-1 and Site-2 are almost identical
in all KCC isoforms (Figure 2), indicating that the phospho-
specific antibodies raised against these residues would probably
detect the equivalent residues on other KCC isoforms. Indeed,
immunoblot and immunoprecipitation analysis revealed that the
KCC3A phospho-specific Site-1 and Site-2 antibodies readily
detected KCC1, KCC2 and KCC4 (Figure 3B) overexpressed
in HEK-293 cells grown in basic control isotonic medium, but to
a lesser extent in cells treated with hypotonic high K+ conditions
that induce the dephosphorylation of these residues.
Linking SPAK/OSR1 with KCC3A phosphorylation and transport
activity
To determine whether activation of the SPAK/OSR1 pathway
promotes phosphorylation of KCC3A at Site-2 and Site-
4, the residues that are phosphorylated in vitro (Figure 2
and Table 1), we exposed HEK-293 cells to hypotonic low
Cl− conditions that stimulate SPAK/OSR1 [4]. We monitored
WNK1 phosphorylation at its activating T-loop residue (Ser382),
SPAK/OSR1 phosphorylation at the residue phosphorylated by
WNK1 (Ser373/Ser325) and NKCC1 phosphorylation at residues
phosphorylated by SPAK/OSR1 (Thr203, Thr207 and Thr212) over
a 30 min time period (Figure 4A). These experiments revealed
that within 5 min of exposing HEK-293 cells to hypotonic
low Cl− conditions, an increase in the phosphorylation of
WNK1, SPAK/OSR1 and NKCC1 was observed, which was
maximal within 10 min and sustained for 30 min. Consistent with
SPAK/OSR1 mediating the phosphorylation of KCC3A at Site-
2 and Site-4, we observed an increased phosphorylation of these
residues within 5–10 min of exposing HEK-293 cells to hypotonic
low Cl− conditions, and this phosphorylation was sustained for
at least 30 min. Exposure of HEK-293 cells to hypotonic low Cl−
conditions also promoted the phosphorylation of KCC at Site-1
over a similar time course as for Site-2 and Site-4 (Figure 4A).
We next analysed KCC3A activity by measuring 86Rb+ uptake
in isotonic or hypotonic low Cl− conditions (Figure 4B).
As expected given that KCC3A is maximally phosphorylated
following hypotonic low Cl− conditions, very low KCC3A
activity was observed (Figure 4B). Individual mutation of either
Site-1 or Site-2 to alanine moderately activated KCC3A, and these
mutants were still significantly inhibited by hypotonic low Cl−
conditions (Figure 4B). In contrast, a KCC3A mutant in which
both Site-1 and Site-2 were mutated to alanine was highly active
and not inhibited further by hypotonic low Cl− conditions, thereby
confirming that these are indeed the essential inhibitory sites.
We also treated HEK-293 cells with hypotonic high K+
conditions to induce dephosphorylation of KCC3A. Time course
analysis revealed that the most pronounced dephosphorylation
of Site-1, Site-2 and Site-4 occurred within 15–30 min. Levels
of WNK1, SPAK/OSR1 and NKCC1 phosphorylation were also
reduced markedly after a 15–30 min exposure to hypotonic
high K+ conditions (Figure 4C). We then analysed KCC3A
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Figure 3 Characterization of phospho-specific KCC Site-1, Site-2 and Site-4 antibodies
(A) HEK-293 cells were transfected with constructs encoding a FLAG empty vector or the indicated wild-type or mutant constructs of N-terminal FLAG epitope-tagged KCC3A. At 36 h post-transfection,
cells were treated with either basic control isotonic or hypotonic high K+ conditions to induce dephosphorylation of KCC3A for 30 min, and were then lysed. Total cell extracts were subjected to
immunoblot (IB) analysis with the indicated phospho-specific antibodies raised against KCC3A Site-1 (pThr991), KCC3A Site-2 (pThr1048) and KCC3A Site-4 (pSer96), as well as total anti-KCC3A
and anti-ERK1 antibodies (upper panels). The lysates were also subjected to immunoprecipitation (IP) with the indicated KCC3A phospho-antibodies, and immunoprecipitates were subjected to
immunoblot analysis employing an anti-FLAG antibody. Similar results were obtained in three separate experiments. (B) Treatment as above, except cells were transfected with constructs encoding
N-terminal FLAG-tagged versions of KCC1, KCC2A and KCC4. Solid lines indicates blots that were run on different gels. Molecular masses are all indicated in kDa on the left-hand side of the
Western blots.
activity by measuring 86Rb+ uptake in isotonic or hypotonic
high K+ conditions (Figure 4D). As expected, hypotonic high
K+ conditions induced a marked activation of wild-type KCC3A
(Figure 4D, upper panel). This was associated with a significant
dephosphorylation of KCC3A Site-1 and Site-2 and a marked
reduction in WNK1, SPAK/OSR1 and NKCC1 phosphorylation
(Figure 4D, lower panel). Individual alanine mutation of Site-
1 and Site-2, preventing phosphorylation at these sites, led to a
moderate activation of KCC3A under isotonic conditions, and
the activity of these mutants was stimulated further following
exposure to hypotonic high K+ conditions. Mutation of both Site-
1 and Site-2, as reported previously [52], resulted in constitutive
activation of KCC3A that was not activated further by hypotonic
high K+ conditions. Individual mutation of Site-4 was found
to have no significant effect on KCC3A activity in isotonic
or hypotonic high K+ conditions (Figure 4D, upper panel), as
reported previously [51].
Pharmacological evidence that SPAK/OSR1 directly phosphorylate
KCC3A Site-2 and Site-4
A small molecule compound termed STOCK1S-50699 has
recently been described that binds the CCT domain
of SPAK/OSR1, thereby preventing WNK-mediated activation of
the SPAK/OSR1, and consequently functioning as a WNK–
SPAK/OSR1 inhibitor [30]. To obtain further evidence that
SPAK/OSR1 regulate KCC3A phosphorylation, we exposed
HEK-293 cells for 30 min to either basic control isotonic
conditions or hypotonic low Cl− (to activate SPAK/OSR1), and
then treated the cells in the same conditions with increasing doses
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of STOCK1S-50699 for an additional 30 min. These experiments
confirmed that 1–10 μM STOCK1S-50699 inhibited markedly,
in a dose-dependent manner, SPAK/OSR1 phosphorylation at
Ser373/Ser325 (i.e. the activating site phosphorylated by WNK1)
and NKCC1 phosphorylation at Thr203/Thr207/Thr212 (SPAK/OSR1
sites whose phosphorylation is required for maximal transporter
activity) in both hypotonic low Cl− conditions, as well as
basic control isotonic conditions (Figure 5). These effects
were paralleled by a similar suppression of KCC3A Site-2
(Thr1048) and Site-4 (Ser96) phosphorylation, consistent with
the phosphorylation of these residues being mediated by
SPAK/OSR1. Phosphorylation of Site-1 was also inhibited by
STOCK1S-50699, but to a lower extent than Site-2 (Figure 5).
Consistent with STOCK1S-50699 promoting dephosphoryla-
tion of Site-2, in 86Rb+ uptake activity assays we observed that this
inhibitor at concentrations over 3 μM stimulated 86Rb+ uptake
even under hypotonic low chloride conditions (Figure 5, upper
panel). STOCK1S-50699 also stimulated 86Rb+ uptake under
control isotonic conditions (Figure 5, upper panel).
Evidence that SPAK/OSR1 regulate the endogenous
phosphorylation and activity of KCC2A, KCC3A and KCC4
To investigate how the lack of SPAK and OSR1 activity affects
endogenous KCC isoform phosphorylation, we utilized previ-
ously described wild-type and double OSR1185A/185A/SPAK243A/243A
knockin ES cells, in which the T-loop phosphorylation site on
SPAK and OSR1, that is phosphorylated by WNK isoforms, is
mutated to alanine to prevent their activating phosphorylation
[29]. Wild-type and knockin cells were treated with basic control
isotonic or hypotonic high K+ conditions for 30 min to induce
dephosphorylation of KCC isoforms, and then the harvested
lysates were subjected to immunoprecipitation with Site-1 and
Site-2 phospho-specific antibodies that immunoprecipitate all
KCC isoforms when phosphorylated at these residues (Figure 3).
The immunoprecipitates were then immunoblotted with
antibodies that specifically recognize different individual KCC
isoforms. In wild-type ES cells, endogenous KCC2A, KCC3A
and KCC4 were phosphorylated at Site-1 and Site-2, as these co-
transporters could readily be immunoprecipitated with the Site-1
and Site-2 phospho-specific antibodies (Figure 6, lower panel). As
expected, immunoprecipitation of KCC2A, KCC3A and KCC4
isoforms was inhibited when wild-type ES cells were treated
with hypotonic high K+ conditions to induce dephosphorylation
of these residues. In the OSR1185A/185A/SPAK243A/243A knockin ES
cells, we still observed that endogenous KCC2A, KCC3A and
KCC4 were phosphorylated at Site-1 to a similar extent as wild-
type cells; however, consistent with SPAK/OSR1 predominately
phosphorylating Site-2, Site-2 phosphorylation in endogenous
KCC2A, KCC3A and KCC4 was abolished in knockin ES cells
lacking SPAK/OSR1 activity (Figure 6, lower panel).
We then analysed endogenous KCCs activity in the
OSR1185A/185A/SPAK243A/243A knockin ES cells by measuring 86Rb+
uptake under basic control isotonic or hypotonic high K+
conditions, and compared these results with wild-type ES cells.
As expected, exposure of wild-type ES cells to hypotonic high
K+ conditions induced a significant ∼2-fold activation of 86Rb+
uptake (Figure 6, upper panel), consistent with KCC activation.
In contrast, in the double OSR1185A/185A/SPAK243A/243A knockin
cells that lack SPAK/OSR1 activity, we observed an elevated
basal activity of 86Rb+ uptake that was not stimulated markedly
further by hypotonic high K+ conditions, suggesting an increase
in KCC activity secondary to decreased phosphorylation at
Site-2 (Figure 6, upper panel). Together, these data provide
evidence that endogenous silencing SPAK/OSR1 kinase activity
is able to stimulate KCC activity by preventing Site-2 inhibitory
phosphorylation.
We also investigated whether the SPAK/OSR1 inhibitor
STOCK1S-50699 would affect the phosphorylation of
endogenous KCC isoforms in either ES cells (Figure 7A) or
HEK-293 cells (Figure 7B). These studies revealed that in both
ES cells and HEK-293 cells treated under either basic isotonic or
hypotonic low chloride conditions, STOCK1S-50699 inhibited
the phosphorylation of KCC3a (ES and HEK-293) and KCC2a
(ES) at Site-2 and Site-4, but not Site-1 (Figure 7).
DISCUSSION
The results of the present study reveal a major direct role for the
WNK-regulated SPAK/OSR1 protein kinases in the regulation
of KCC phosphorylation and function. Our data provide the
first biochemical (Figure 1 and Table 1), pharmacological
(Figure 5) and genetic (Figure 6) evidence that SPAK/OSR1
phosphorylates directly all KCC isoforms at the critical regulatory
Site-2 residue (Thr1048 in KCC3A) [42]. We also confirmed
that SPAK/OSR1 phosphorylates directly a previously defined
KCC3A-specific residue termed Site-4 (Ser96) [51]. Although the
dephosphorylation of Site-1 and Site-2 plays the most important
role in activating KCC isoforms [42], recent work has shown that
dephosphorylation of Site-4 is also required for maximal KCC3A
activation [51]. In addition to the finding that SPAK/OSR1
phosphorylates directly residues known to critically inhibit KCC
function (Site-2 and Site-4), we have identified a novel N-terminal
phosphorylation site (Site-3) present in all KCC isoforms except
KCC3A (Thr5 in KCC1/KCC3 and Thr6 in KCC2A/KCC4) that
is also phosphorylated directly by SPAK/OSR1 (Figure 2 and
Table 1). Together, these data unambiguously define WNK-
regulated SPAK/OSR1 as key regulators of KCC activity via direct
inhibitory phosphorylation at multiple critical residues.
Our findings indicate that the MO25α subunit is required for
efficient phosphorylation of KCC isoforms by SPAK/OSR1, at
least in vitro (Figure 1). This is consistent with MO25α playing an
essential role in stabilizing WNK-phosphorylated SPAK/OSR1 in
an active conformation that can then efficiently phosphorylate
its substrates [25]. These data emphasize the importance of
including the MO25α subunit in future studies for identification
Figure 4 SPAK/OSR1 kinase activity correlates with KCC3A phosphorylation status and KCC3A transport activity
(A and C) HEK-293 cells were transfected with constructs encoding wild-type N-terminal FLAG epitope-tagged KCC3A. At 36 h post-transfection, cells were treated for the indicated times with
hypotonic low Cl− conditions (to activate SPAK/OSR1 pathway) (A) or hypotonic high K+ conditions (to induce dephosphorylation of KCC3A) (C). Cells were immediately lysed and cell extracts
were subjected to immunoblot (IB) and analysis with the indicated total and phospho-specific antibodies. (B and D) As above, except that the wild-type and the indicated mutant of KCC3A species
were transfected into HEK-293 cells. Mutations are at: Site-1 (KCC3A [T991A]), Site-2 (KCC3A [T1048A]) and Site-4 (KCC3A [S96A]). At 36 h post-transfection, cells were treated for 30 min with
either hypotonic low Cl− conditions (B) or hypotonic high K+ conditions (D). 86Rb+ uptake was measured in the presence of 1 mM ouabain (inhibitor of the plasma membrane Na+ /K+ -ATPase
sodium pump) and 0.1 mM bumetanide (inhibitor of NKCC1) in the uptake medium (for details, see the Materials and methods section). 86Rb+ -uptake assays were then carried out over a 10 min
period and was then quantified by scintillation counting. 86Rb+ uptake c.p.m. were normalized per mg of protein for each condition and plotted for both isotonic and hypotonic conditions. The
results are presented as the means +− S.D. 86Rb+ uptake for triplicate samples. Lysates were also subjected to immunoblot analysis with the indicated total and phospho-specific antibodies. Similar
results were obtained in three separate experiments.
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Figure 5 The WNK–SPAK/OSR1 CCT domain inhibitor STOCK1S-50699 suppresses phosphorylation of KCC3A Site-2 and Site-4
HEK-293 cells were transfected with constructs encoding wild-type N-terminal FLAG epitope-tagged KCC3A. At 36 h post-transfection cells were exposed for 30 min to either basic control isotonic
conditions or hypotonic low Cl− conditions (to activate the SPAK/OSR1 pathway), and then treated in the same conditions with the indicated doses of the SPAK/OSR1 CCT domain inhibitor
STOCK1S-50699 [30] for an additional 30 min in the presence of 1 mM ouabain (an inhibitor of the plasma membrane Na+ /K+ -ATPase sodium pump) and 0.1 mM bumetanide (inhibitor of
NKCC1). 86Rb+ uptake proceeded for 10 min and was then quantified by scintillation counting. 86Rb+ uptake c.p.m. values were normalized per mg of protein for each condition and plotted for
both isotonic and hypotonic conditions. Cells were lysed and extracts were subjected to immunoblot analysis with the indicated total and phospho-specific antibodies (lower panel). Similar results
were obtained in three separate experiments.
of novel SPAK/OSR1 substrates. Our conclusion that
SPAK/OSR1 operate as key direct regulators of KCC isoforms
is consistent with previous observations that found that
knockdown of WNK1 expression, which would be expected
to suppress SPAK/OSR1 activity, decreased phosphorylation
of KCC3A at Site-2 (Thr1048) [42]. Similarly, the observation
that overexpression of wild-type WNK3 (and WNK4),
predicted to activate SPAK/OSR1, inhibits KCC isoforms in
oocytes [39,40,43–45], but overexpression of a kinase-dead
WNK3, predicted to inhibit SPAK/OSR1 in a dominant-negative
mechanism, potently activates KCC isoforms in oocytes [39], is
congruent with our conclusions that SPAK/OSR1, regulated by
WNK kinase activity, play an important role in controlling KCC
phosphorylation and activity.
Interestingly, our data suggest that SPAK/OSR1 may not
phosphorylate directly the important Site-1 (Thr991 in KCC3A)
regulatory residue on KCC isoforms. The strongest and most
direct evidence to support this conclusion is the finding that
three endogenous KCC isoforms (KCC2, KCC3 and KCC4) are
still phosphorylated on Site-1, but not on Site-2, in knockin
ES cells that lack SPAK/OSR1 activity (Figure 6). Therefore,
at least in ES cells that lack SPAK and OSR1 activity,
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Figure 6 WNK–SPAK/OSR1 regulation and phosphorylation of endogenous KCCs
Previously described matched wild-type and double OSR1185A/185A/SPAK243A/243A knockin ES cells [29], in which SPAK/OSR1 are inactive as the T-loop phosphorylation site that is phosphorylated by
WNK isoforms is ablated, were incubated with either basic control isotonic medium (open bars) or hypotonic high K+ medium (closed bars) for 30 min in the presence of 1 mM ouabain (an inhibitor
of the plasma membrane Na+ /K+ -ATPase sodium pump) and 0.1 mM bumetanide (inhibitor of NKCC1). 86Rb+ uptake proceeded for 10 min and was then quantified by scintillation counting.
86Rb+ uptake c.p.m. values were normalized per mg of protein for each condition and plotted for both isotonic and hypotonic conditions. The lysates were also subjected to immunoprecipitation (IP)
with the indicated KCC3A Site-1 and Site-2 phospho-antibodies that recognize all KCC isoforms (see Figure 3). The immunoprecipitates were then immunoblotted employing the indicated specific
KCC isoform antibodies. Molecular masses are indicated in kDa on the left-hand side of the Western blots (lower panel). Similar results were obtained for three separate experiments.
another currently unknown kinase must exist that can efficiently
phosphorylate Site-1. We also found that SPAK/OSR1 did not
phosphorylate KCC isoforms at Site-1 in vitro (Figure 1 and
Table 1). However, the finding that knockdown of WNK1
partially reduced phosphorylation of KCC3A at Site-1 [42], does
suggest WNK isoforms regulate KCC phosphorylation at Site-
1, either directly upstream of another kinase or perhaps via the
regulation of a phosphatase. It would also appear that WNK1 itself
does not directly phosphorylate Site-1, as we have also tested
whether endogenously immunoprecipitated WNK1 is capable of
phosphorylating Site-1 directly on isolated KCC fragments or
full-length immunoprecipitated KCC3A. We found that under
conditions that WNK1 efficiently phosphorylates catalytically
inactive OSR1, no marked phosphorylation of Site-1 or Site-2
was observed when employing the phospho-specific antibodies
as readouts for this activity (P. de los Heros, unpublished work).
Further work is required to understand how WNK isoforms might
control Site-1 phosphorylation and to what extent SPAK/OSR1
is involved. It may be that other WNK isoforms, such as
WNK3, are directly involved in KCC Site-1 regulation, given
the activating effects of kinase-dead WNK3 on KCCs in vitro
[39]; this is one obvious candidate requiring further detailed
biochemical examination. Also consistent with a role for the
WNK–SPAK/OSR1 cascade regulating Site-1 phosphorylation,
we observed that the CCT domain inhibitor STOCK1S-50699
partially suppresses KCC3A Site-1 phosphorylation, albeit to
a lesser extent than its inhibition of SPAK/OSR1 activity and
KCC3A Site-2 phosphorylation (Figure 5). Notably, to check
the selectivity of STOCK1S-50699, we assessed the effect of
a high concentration of this inhibitor (10 μM) on the activity
of 150 protein kinases in vitro and found that it does not
significantly inhibit the activity of any other kinase, confirming
that this compound is not a general protein kinase inhibitor
(http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors).
Our data emphasize that the phosphorylation of Site-1,
Site-2 and Site-4 are co-ordinately regulated. For example,
following exposure of cells to conditions that activate the
WNK signalling pathway (hypotonic low Cl− ), we observed a
stimulation of phosphorylation of Site-1 and Site-2 of the KCCs,
closely accompanied with increased phosphorylation of WNK1,
SPAK/OSR1 and NKCC1 (Figure 4A). Conversely, exposure
of cells to conditions that inhibit the WNK signalling network
(hypotonic high K+ ) resulted in dephosphorylation of Site-1 and
Site-2 in the KCCs, as well as WNK1, SPAK/OSR1 and NKCC1
(Figure 4C). One important unresolved question concerns the
mechanism by which extracellular conditions, such as hypotonic
high K+ , are detected, and how this signal is transduced to trigger
the dephosphorylation of WNK pathway components and KCC
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Figure 7 STOCK1S-50699 inhibits phosphorylation of endogenous KCC isoforms at Site-2 and Site-4 in ES and HEK-293 cells
ES (A) or HEK-293 (B) cells were exposed for 30 min to either basic control isotonic conditions or hypotonic low Cl− conditions (to activate the SPAK/OSR1 pathway), and then treated under the
same conditions with the indicated doses of the SPAK/OSR1 CCT domain inhibitor STOCK1S-50699 [30] for an additional 30 min. The lysates were subjected to immunoprecipitation (IP) with
the indicated KCC3A Site-1, Site-2 and Site-4 phospho-antibodies that recognize all KCC isoforms (see Figure 3). The immunoprecipitates were then immunoblotted (IB) employing the indicated
specific KCC isoform antibodies. Cells lysates were also subjected to immunoblot analysis with the indicated total and phospho-specific antibodies. Similar results were obtained in three separate
experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
isoforms. Protein phosphatase(s) and their associated regulatory
subunits that tether these enzymes to their targets are likely to
play a critical role in this pathway, illustrated by the fact that
all KCC isoforms, as well as core WNK pathway components,
are robustly dephosphorylated within 15 min of exposure of cells
to hypotonic high K+ conditions (Figure 4C). Several previous
studies have highlighted that several general protein phosphatase
inhibitors [40,53] block activation of KCC isoforms. Previous
work has also implicated protein phosphatase-4 in the de-
phosphorylation of NCC at the critical Thr60 regulated by the
WNK–SPAK/OSR1 pathway [54]. In future studies, it would be
important to determine the identity of the protein phosphatase
catalytic activity, as well as the targeting regulatory subunit, that
acts on the KCC isoforms, and to determine further whether
the activity of this phosphatase complex is regulated by osmotic
conditions. It would also be important to define whether the same
or different protein phosphatase complexes act on different KCC
isoforms and components of the WNK signalling system.
The importance of co-ordinating cellular Cl− influx and efflux
has long been appreciated [9,17]. The finding that SPAK/OSR1
kinases phosphorylate and thereby trigger activation of the
Na+ -driven Cl− influx co-transporters (NKCC1, NKCC2 and
NCC) and also phosphorylate and inhibit K+ -driven Cl− efflux
co-transporters (KCC1, KCC2, KCC3 and KCC4), provides
a simple mechanism to explain how these critical Na+ and
K+ co-transporters are reciprocally and co-ordinately controlled
(Figure 8). Stimuli such as hypotonic low Cl− conditions that
activate the WNK–SPAK/OSR1 pathway will induce net cellular
Cl− absorption by promoting phosphorylation, thereby activating
the N[K]CCs and concurrently inhibiting the KCCs. In contrast,
stimuli that inactivate the WNK–SPAK/OSR1 pathway, such
as hypotonic high K+ conditions, will suppress cellular Cl−
absorption by promoting dephosphorylation, thereby inhibiting
the N[K]CCs and concurrently stimulating the KCCs. This co-
ordinated and potent mechanism, with opposite effects on the
main Cl− influx and Cl− efflux mediators involved in cellular
Cl− homoeostasis, is of obvious interest for drug development.
Our data suggest that this mechanism is druggable by the targeting
of the CCT domain within SPAK/OSR1, which interferes with
WNK activation. Given the anticipated net effects of WNK–
SPAK/OSR1 signalling on increasing cellular Cl− influx, we
propose that the inhibition of this pathway with kinase inhibitors
resembling STOCK1S-50699 might be a novel potent strategy to
enhance cellular Cl− extrusion. The phenotypes of human and
mice with alterations in the WNK–SPAK/OSR1 pathway suggest
that such a drug might be a novel K+ -sparing diuretic with special
potency as an anti-hypertensive, since it would suppress renal salt
re-absorption (and via effects on intravascular volume, blood pres-
sure) in a more co-ordinated and balanced manner than thiazide
and loop diuretics, which only suppress the activity of NCC
(thiazide) or NKCC2 (loop diuretics) individually. Moreover,
given the recent interest and proof of concept of small molecule
enhancers of neuronal Cl− extrusion via KCC2 activation to
treat diseases featuring GABAergic (GABA is γ -aminobutyric
acid) disinhibition secondary to impaired KCC2 activity [55,56],
we propose that an especially potent way to enhance neuronal
Cl− extrusion would be to concurrently inhibit Cl− influx via
NKCC1 and activate Cl− efflux via KCC2 [57]; our results
suggest this could be done by inhibiting WNK–SPAK/OSR1
signalling. These hypotheses are testable, given the existence of a
c© The Authors Journal compilation c© 2014 Biochemical Society
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Figure 8 Proposed mechanism of reciprocal regulation of the N[K]CC and KCC co-transporters by the WNK–SPAK/OSR1 cascade
SPAK/OSR1 are activated by WNK isoforms and then phosphorylate the NTD of the Na+ -driven CCCs (NKCC1, NKCC2 and NCC), thereby stimulating influx of Cl− (and Na+ ). Work undertaken
in the present study establishes that SPAK/OSR1 also phosphorylates K+ -driven CCCs (KCC1, KCC2, KCC3 and KCC4) at residues located in both their NTD and CTD, thereby stimulating efflux
of Cl− (and K+ ). Phosphorylation of Site-2 by SPAK/OSR1 greatly contributes to the regulation of the KCC activity. Site-1 phosphorylation also plays a major role in regulating KCC activity; the
present study indicates that SPAK/OSR1 may not itself phosphorylate this site directly, but WNKs and/or SPAK/OSR1 may influence the activity of the kinase that phosphorylates Site-1. Further work
is required to establish the roles that Site-3 phosphorylation within the NTD plays. Site-4 is only present in the KCC3 and KCC3A splice variants, and previous work suggests that phosphorylation
at this site plays a minor role in regulating KCC activity [51].
WNK–SPAK/OSR1 inhibitor and phospho-specific antibody
readouts of pathway activity, with potential implications for the
therapeutic modulation of epithelial and neuronal ion transport.
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